Peregrine Pharma (PPHM) Resumes Trading, Now Up 16.6%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
UPDATE: Peregrine Pharmas (PPHM) to Resume 1:20PM ET; Shares Up 11%+ Ahead of Halt
September 7, 2012 12:57 PM EDT(Updated - September 7, 2012 12:58 PM EDT)
Peregrine Pharmaceuticals (Nasdaq: PPHM) to resume trading at 1:20PM ET after data.
Notably, shares were up about 11 percent ahead of the halt and very volatile on the session.... More
Peregrine Pharma (PPHM) Reports Statistically Significant Data from Bavituximab Phase IIb
September 7, 2012 12:53 PM EDTPeregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC).
The blinded study evaluated two dose levels of bavituximab (bavituximab-containing arms) given with docetaxel versus docetaxel... More
Peregrine Pharmaceuticals (PPHM) halted, news pending
September 7, 2012 11:57 AM EDTPeregrine Pharmaceuticals (Nasdaq: PPHM) halted, news pending... More
